PMID- 25456098 OWN - NLM STAT- MEDLINE DCOM- 20150224 LR - 20221207 IS - 1532-8600 (Electronic) IS - 0026-0495 (Linking) VI - 64 IP - 2 DP - 2015 Feb TI - Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. PG - 213-7 LID - S0026-0495(14)00304-7 [pii] LID - 10.1016/j.metabol.2014.10.011 [doi] AB - BACKGROUND: Leukocyte activation has been associated with vascular complications in type 2 diabetes mellitus (T2DM). Hyperglycemia may be involved in this leukocyte activation. Our aim was to investigate the role of elevated glucose concentrations on leukocyte activation in patients with a wide range of insulin sensitivity. METHODS: Leukocyte activation was determined after ingestion of 75 gram glucose in subjects with T2DM, familial combined hyperlipidemia (FCH) and healthy controls. Leukocyte activation markers were measured by flow cytometry. Postprandial changes were calculated as the area under the curve (AUC), and the incremental area under the curve corrected for baseline values (dAUC). RESULTS: 51 Subjects (20 T2DM, 17 FCH and 14 controls) were included. Fasting neutrophil CD66b expression and CD66b-AUC were respectively 36% and 39% higher in T2DM patients than in controls (p=0.004 and p=0.003). Fasting neutrophil CD66b expression correlated positively with glucose-AUC (Spearman's rho 0.481, p<0.001) and HbA1c (rho 0.433, p=0.002). Although fasting monocyte CD11b expression was not significantly different between subjects, monocyte CD11b-AUC was 26% higher in T2DM than in controls (p=0.006). Similar trends were observed for FCH patients. Monocyte CD11b-dAUC correlated positively with glucose-AUC (rho 0.322, p=0.022) and HbA1c (rho 0.319, p=0.023). CONCLUSIONS: These data suggest that both acute and chronic hyperglycemia, associated with insulin resistance as seen in T2DM and FCH, are involved in the increased fasting and postprandial leukocyte activation observed in these conditions. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - de Vries, Marijke A AU - de Vries MA AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. Electronic address: m.devries@sfg.nl. FAU - Alipour, Arash AU - Alipour A AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Klop, Boudewijn AU - Klop B AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - van de Geijn, Gert-Jan M AU - van de Geijn GJ AD - Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Janssen, Hans W AU - Janssen HW AD - Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Njo, Tjin L AU - Njo TL AD - Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - van der Meulen, Noelle AU - van der Meulen N AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Rietveld, Arie P AU - Rietveld AP AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Liem, Anho H AU - Liem AH AD - Department of Cardiology, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - Westerman, Elsbeth M AU - Westerman EM AD - Department of Clinical Pharmacy, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. FAU - de Herder, Wouter W AU - de Herder WW AD - Department of Endocrinology, Erasmus Medical Center Rotterdam, The Netherlands. FAU - Cabezas, Manuel Castro AU - Cabezas MC AD - Department of Internal Medicine, Center for Diabetes and Cardiovascular Risk Management, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. LA - eng SI - ClinicalTrials.gov/NCT01634906 SI - ClinicalTrials.gov/NCT02130505 PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141016 PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (Antigens, CD) RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (CD11b Antigen) RN - 0 (CEACAM8 protein, human) RN - 0 (Cell Adhesion Molecules) RN - 0 (GPI-Linked Proteins) RN - 0 (Glycated Hemoglobin A) RN - 0 (ITGAM protein, human) RN - 0 (hemoglobin A1c protein, human) SB - IM MH - Antigens, CD/blood/metabolism MH - Biomarkers/blood/metabolism MH - Blood Glucose/analysis MH - CD11b Antigen/blood/metabolism MH - Cell Adhesion Molecules/blood/metabolism MH - Diabetes Mellitus, Type 2/blood/*immunology/metabolism/physiopathology MH - Female MH - GPI-Linked Proteins/blood/metabolism MH - Glucose Tolerance Test MH - Glycated Hemoglobin/analysis MH - Humans MH - Hyperglycemia/*etiology MH - Hyperlipidemia, Familial Combined/blood/*immunology/metabolism/physiopathology MH - *Insulin Resistance MH - Leukocytes/*immunology/metabolism MH - Male MH - Middle Aged MH - Monocytes/immunology/metabolism MH - Neutrophils/immunology/metabolism MH - Up-Regulation OTO - NOTNLM OT - Atherosclerosis OT - Diabetic complications OT - Inflammation OT - Integrin EDAT- 2014/12/03 06:00 MHDA- 2015/02/25 06:00 CRDT- 2014/12/03 06:00 PHST- 2014/08/06 00:00 [received] PHST- 2014/09/27 00:00 [revised] PHST- 2014/10/12 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2015/02/25 06:00 [medline] AID - S0026-0495(14)00304-7 [pii] AID - 10.1016/j.metabol.2014.10.011 [doi] PST - ppublish SO - Metabolism. 2015 Feb;64(2):213-7. doi: 10.1016/j.metabol.2014.10.011. Epub 2014 Oct 16.